How much is a coronavirus drug worth to Alnylam? At least $15 million
Last week, Alnylam and Vir announced they would work together to develop a new coronavirus drug. It seemed rather sensible; Vir has the infectious disease experts, Alnylam has the tech, and the two companies had a pre-existing partnership.
New details revealed in an SEC filing this week provide a little more insight into exactly what that deal will entail. If Vir actually winds up developing a drug, it could owe Alnylam up to $15 million.
Also interesting: If that drug makes it to market, Vir will pay Alnylam some royalties based on sales — but those royalties will be only“in the low single digits” for “sales to governmental authorities or sales for the purposes of biodefense, management of public health or other public policy reasons.”
New details revealed in an SEC filing this week provide a little more insight into exactly what that deal will entail. If Vir actually winds up developing a drug, it could owe Alnylam up to $15 million.
Also interesting: If that drug makes it to market, Vir will pay Alnylam some royalties based on sales — but those royalties will be only“in the low single digits” for “sales to governmental authorities or sales for the purposes of biodefense, management of public health or other public policy reasons.”
.png)
No hay comentarios:
Publicar un comentario